Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

SGMT EBITDA Margin

EBITDA as a percentage of revenue.

Sagimet Biosciences Inc.NASDAQ: SGMT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
-1393.8%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SGMT compares with its peers on the latest reported figures

SGMT Competitors Peer median
EBITDA Margin for SGMT and competitors
Company Period LTM level YoY 3-year change
ASMBAssembly Biosciences, Inc.LTM Mar 2026-8.8% +113.4 pp—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-257.0% +77.3 pp+319.4 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-308.4% -186.1 pp-189.2 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-2873.3% -2889.4 pp—
HUMAHumacyte, Inc.LTM Mar 2026-3956.7% -3182.9 pp-1247.4 pp
SGMTSagimet Biosciences Inc.FY2025— ——
ACHVAchieve Life Sciences, Inc.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
ZURAZura Bio LimitedFY2025— ——
Peer median (excluding SGMT) -282.7%-143.4 pp-145.0 pp

Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue002M00
Cost of Revenue00000
Gross Profit002M00
Gross Margin——100.0%——
Research & Development19.34M24.92M19.78M38.44M39.05M
Selling, General & Admin4.38M6.14M12.96M16.01M17.84M
Operating Expenses23.72M31.06M32.74M54.45M56.89M
Depreciation & Amortization0130K000
EBITDA(24.44M)(30.37M)(27.88M)(45.57M)(51.04M)
EBITDA Margin——-1393.8%——
Operating Income(23.72M)(31.06M)(30.74M)(54.45M)(56.89M)
Operating Margin——-1537.0%——
Interest Income26K553K2.86M8.89M5.85M
Interest Expense00000
Other Income / Expenses(723K)556K2.86M8.89M5.85M
Income Before Tax(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Pre-Tax Margin——-1393.8%——
Income Tax Expense00000
Net Income(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Net Margin——-1393.8%——
EPS (Basic)(1.10)(1.38)(1.53)(1.45)(1.58)
EPS (Diluted)(1.10)(1.38)(1.53)(1.45)(1.58)
Weighted Avg Shares22.17M22.17M18.19M31.35M32.35M
Weighted Avg Shares (Diluted)22.17M22.17M18.19M31.35M32.35M

Sagimet Biosciences Inc.

NASDAQ:SGMT

Intrinsic Alpha fair value

Locked

Current Price

$10.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.